Key Highlights

  • Ensysce Biosciences shares closed up 45% at $0.52.
  • The company finalized the acquisition of Cy Biopharma, Inc.
  • The deal integrates neuroplastogenic candidate CY200, which holds FDA Orphan Drug Designation for CRPS.
  • The transaction is supported by approximately $77 million in aggregate capital commitments.

Ensysce Biosciences, Inc. (NASDAQ: ENSC) shares closed up 45% at $0.52 after the company finalized the acquisition of Cy Biopharma, Inc., integrating the neuroplastogenic candidate CY200 into its development pipeline.

What Happened

CY200 holds FDA Orphan Drug Designation for Complex Regional Pain Syndrome (CRPS). The strategic transaction is supported by approximately $77 million in aggregate capital commitments, including private placements led by Ally Bridge Group and milestone-dependent funding.

Market Reaction

Shares surged as investors responded to the combination of the pipeline-expanding acquisition and the substantial capital raise supporting it, with the funding projected to provide a financial runway through Phase 2 proof-of-concept for CY200.

Outlook

CY200 targets a billion-dollar market opportunity with no currently approved treatments, while the company simultaneously progresses its opioid abuse-resistant platform with NIDA support, both of which are likely to remain relevant to the stock's trajectory going forward.

Why did Ensysce Biosciences shares surge 45%?

Shares rose after the company finalized its acquisition of Cy Biopharma, integrating CY200 into its pipeline, backed by approximately $77 million in capital commitments.

What designation does CY200 hold?

FDA Orphan Drug Designation for Complex Regional Pain Syndrome (CRPS).

How far does the new funding extend the company's runway?

Through Phase 2 proof-of-concept for CY200.